|
|
Expression Pattern Group C, enriched for genes involved in metabolic processes. |
The significance (P 0.0001) of the relative age (time) was used to determine if a gene was differentially expressed between the three age (time) groups. The effect of this factor explaining gene expression differences was used to determine if the expression went up or down during the two age/time periods (t1 - t2 and t2 -t3). Authors used a permutation approach to determine the thresholds for the different mapping strategies. For each of the used models for eQTL mapping, authors used 23,000 permutations. For each permutation, authors randomly picked a spot; each spot could only be picked once. The gene expression and relative lifespan values were than randomly distributed over the RILs (and time points) and used for mapping. In this way, authors obtained a threshold for each of the explaining factors. For the single time points, authors used a FDR of 0.01 to adjust for multiple testing. The genome-wide threshold for this FDR is -log10 P = 3.8 for each of the three time points. For the combined models (t1 to t2 and t2 to t3), authors used a genome-wide threshold of -log10 P = 4, which resembles an FDR of 0.006, 0.001, and 0.006 for marker, age, and the interaction between marker and age, respectively. To determine the threshold for the single gene examples, authors used 1000 permutations as in the genome-wide threshold. The difference is that they use the gene under study in all of the permutations. The P-values for the gene specific thresholds were determined at FDR = 0.05. |
WBPaper00036286:Pattern_C
|
|
|
Genes that showed significant differential expressed between control and 150 mg\/L Atrazine treatment. |
t-test, p < 0.05. |
WBPaper00036123:Atrazine_regulated
|
|
|
Genes up-regulated following nhr-25(RNAi). |
Pair-wise significance testing (mutant/RNAi vs. wild-type/vector) was performed using the Bioconductor package limma and p-values were initially corrected for multiple testing using the false discovery rate (FDR) method of Benjamini and Hochberg. Authors defined differential expression as log2(ratio) >= 0.848 with the FDR set to 5%, and p-value <= 0.001. |
WBPaper00045015:nhr-25(RNAi)_upregulated
|
|
|
Transcripts with significantly decreased expression in nuo-6(qm200) vs. N2, and in nuo-6(qm200);ced-4(n1162) vs. ced-4(n1162). |
Comparisons of each genotype were compared to the wild-type using the Empirical Base (Wright & Simon) algorithm and fold changes were represented on a log2 scale. A threshold of p < 0.05 and a fold change of 1.3 (log2) was set to determine differentially expressed targets. |
WBPaper00045263:nuo-6(qm200)_downregulated
|
|
Warm/Cold cycle |
Transcripts that cycle in warm/cold (WC) condition but not in constant cold (CC) condition (pF24<0.02). |
ANOVA prescreening and Fourier analysis. |
WBPaper00037695:WC_5-day
|
|
|
Genes up regulated in the absence of TDP-1, when the threshold was set at a fold change (FC) of 1.2. |
The management and statistical analysis of the microarray data were performed using the Partek Genomic Suite (Partek, Missouri) and Spotfire DecisionSite software (TIBCO, California). |
WBPaper00040603:tdp-1(lf)_up_vs_N2_FC_1.2
|
|
|
Genes that showed significant differential expressed between control and 1000 mg\/L Fluoranthene treatment. |
t-test, p < 0.05. |
WBPaper00036123:Fluoranthene_regulated
|
|
Bacteria infection: Staphylococcus aureus RN6390 |
Genes with altered expression after 8 h S. aureus infection. |
The two conditions were then compared in Resolver to determine fold change for each probe set and a p-value, using a modified t test. Genes with a 2-fold or greater fold change and a p-value ,0.01 were considered differentially expressed. |
WBPaper00036464:S.aureus-RN6390_regulated
|
|
|
mRNAs that showed decreased expression after 100ug\/L microcystin-LR exposure. |
Differentially expressed genes (DEGs) were identified with a random-variance t-test and an SAM (Significance Analysis of Microarrays) test. Gene expression differences were considered statistically significant if their p-value was less than 0.05, the false discovery rate less than 0.3 and the fold-change compared to control at least <= 0.67 or >= 1.5. |
WBPaper00045807:microcystin-LR_downregulated
|
